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Abstract: 
This study evaluated the effectiveness of ibuprofen in treating delayed onset muscle soreness 
(DOMS) of the elbow flexors when taken prior to and following exercise. Twenty subjects 
receive either 2,400 mg/day ibuprofen or a placebo four times per day. Subjects performed 
intense eccentric exercise of the elbow flexors to elicit DOMS. Concentric and eccentric peak 
torque production against an isokinetic resistance of 0.52 rad/s, range of motion at the elbow, and 
subjective soreness of the elbow flexors were measured. ANOVA indicated no significant group-
by-time interaction for concentric peak torque, eccentric peak torque, or pain. A significant 
interaction was revealed for range of motion. There was a significant difference within each 
group's ROM but no interaction between groups. It was concluded that the use of 2,400 mg/day 
ibuprofen prior to and following intense eccentric exercise was no more effective than a placebo 
in treating DOMS of the elbow flexors. 
 
Article: 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly being utilized as a therapeutic 
modality to treat athletic injuries. The most common athletic injuries, that is, sprains, strains, and 
contusions, are frequently characterized by inflammation and pain, and NSAIDs are often used 
to minimize these characteristics. Because NSAIDs act primarily through the inhibition of an 
enzyme-mediated pathway of prostaglandin production, they are used to alter the inflammatory 
response underlying prostaglandin synthesis (18). 
 
The NSAID ibuprofen, in addition to altering prostaglandin production, also exhibits analgesic 
effects (13, 18, 19) and is used for mild pain relief. While not as potent as some of the NSAIDs 
in the same class, such as naproxen (Naprosyn), ibuprofen is an effective anti-inflammatory 
agent because it inhibits cyclo-oxygenase activity (1, 3, 14, 18, 20). Cyclo-oxygenase is the 
primary mediator in the metabolism of arachidonic acid, a phospholipid present in cell 
membranes that is released during cell membrane disruption. This metabolic process yields 
prostaglandins as a product (4, 18). Prostaglandins, along with another cyclo-oxygenase product, 
prostacyclin, play the primary roles in inflammation as both are potent vasodilators and pain-
producing agents (18). 
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With respect to inflammatory-characterized pathologies, Smith et al. (20) reported that arthritic 
patients treated with ibuprofen had reduced joint swelling, pain, and duration of morning 
stiffness as well as increased strength and time to onset of fatigue. In a study of athletic injuries, 
Muckle (19) showed that professional soccer players suffering from comparable soft tissue 
injuries were able to return to competition an average of 3 days earlier when taking 2,400 mg/ 
day ibuprofen than when taking 3,600 mg/day aspirin. Bourne (2) showed that of 55 athletes 
suffering from similar grades of acute athletic injuries, 14 of 28 subjects receiving ibuprofen 
were able to resume activity within 2 days following injury and only 5 of 27 subjects receiving 
an analgesic (paracetamol) were able to return within 2 days of injury. 
 
A combination of clinical symptoms that often occur subsequent to muscle injury and that are 
often treated with nonprescription NSAIDs is termed delayed onset muscle soreness (DOMS). 
Although temporary, DOMS is often a very debilitating condition that can adversely affect 
performance or discourage activity altogether. The response of muscle tissue to exercise, 
especially eccentric action of high intensity or prolonged exercise, is initially catabolic (8, 9, 21). 
Theoretically, the immediate breakdown of the tissue structure could be treated using NSAID 
therapy in an effort to reduce the inflammatory response that follows muscle tissue damage at the 
cellular level. The extent of exercise-induced damage and the subsequent inflammatory response 
depends upon the type, intensity, and duration of exercise. Eccentric contraction of a muscle 
against resistance produces more damage to the muscle fiber than does concentric exercise (21). 
Eccentric contraction is also cited as the primary cause of exercise-induced muscle soreness and 
DOMS (6, 9, 21). 
 
Physiological characteristics of muscle damage, such as soreness, swelling, decreased range of 
motion, and decreased strength, have traditionally been treated therapeutically with various 
modalities (e.g., cryotherapy, heat, exercise, massage, etc.). It is also common for the clinician to 
recommend NSAIDs to decrease the magnitude of these characteristics. Investigation into the 
effects of ibuprofen on the symptoms associated with muscle damage has been minimal. Hasson 
et al. (15) found that independent groups taking either 400 mg ibuprofen three times per day 
beginning 4 hr prior to exercise or a group taking 400 mg ibuprofen three times per day 
beginning 24 hr after exercise experienced significantly less pain 48 hr postexercise and a 
significantly smaller decline in muscular strength 48 hr postexercise compared to a control group 
and a placebo group. In contrast to these findings, Donnelly et al. (6) found that ibuprofen did 
not differ from a placebo in the treatment of pain and decreased muscular strength and endurance 
associated with DOMS in the quadriceps through 72 hr postexercise. 
 
The purpose of this study was to determine if a 2,400 mg/day dosage of ibuprofen prior to and 
following exercise would alter the subjective pain, decreased range of motion, and decreased 




Ten male and 10 female healthy subjects (22.1 ± 6.9 years, 172.5 ± 10.3 cm, 66.8 ± 19.5 kg) 
were recruited to participate in this study. None of the subjects had a known allergy to aspirin or 
ibuprofen, had performed upper body weight training within the previous 6 months, or were 
experiencing pain in the arms. The DOMS-inducing exercise protocol was thoroughly explained 
to all subjects and they read and signed an informed consent form approved by the University of 
Virginia Human Investigation Committee. The subjects were asked to refrain from using any 
medications or other therapeutic modalities for the duration of the study. 
 
Subjects were assigned on a double-blind basis into two groups of 10 subjects. Randomization 
resulted in one group (control) consisting of 8 males and 2 females, the other (experimental) of 8 
females and 2 males. The experimental group received 2,400 mg/day ibuprofen (600 mg four 
times per day) for 5 days; the control group received an identical-appearing placebo that was 
taken four times per day for 5 days. Ingestion of ibuprofen or the placebo began at 0 hr and was 
followed 24 hr later by a pretest to determine concentric and eccentric elbow flexor peak torque, 
elbow range of motion (active elbow extension), and subjective soreness felt in the elbow flexor 
muscles. Immediately following the pretest, each subject completed an intense eccentric exercise 
session that induced DOMS. 
 
Testing Protocol 
Peak Torque. Concentric and eccentric peak torques (PT) were measured on a Kin Com 
isokinetic dynamometer (Chattecx Corporation, Hixon, TN) against a set velocity of 0.52 rad/s 
(30°/s). Each subject was seated with the nondominant arm positioned at approximately 70° 
shoulder flexion and 45° elbow flexion. After a familiarization protocol and a 2-min rest period, 
subjects were asked to maximally contract the elbow flexors concentrically through a 45° to 120° 
arc of active elbow flexion. Subjects were given a brief rest and were instructed to maximally 
contract eccentrically against the resistance arm's movement back to the 45° starting position. 
This two-contraction sequence was performed three times. The three concentric and the three 
eccentric curves were then independently averaged to produce individual average torque curves 
for concentric and eccentric contractions. The highest value of each curve was used as the PT 
value for data analysis. Because of the mixed-gender subject pool and the unequal distribution of 
males and females in the two groups, peak torque was expressed as Newton- meters per kilogram 
of body weight to minimize the effect of absolute strength differences that are normally present 
between genders. 
 
Range of Motion. Elbow range of motion (ROM) was measured goniometrically by the same 
researcher throughout the duration of the study. Subjects were seated with the shoulder at 
approximately 90° flexion and were instructed to actively move the elbow into full extension, 
either to physiological limitation or to pain tolerance. The measurement of elbow extension on a 
360° goniometric scale was then recorded. This procedure was repeated and the two measures 
were averaged to produce a mean measurement of elbow extension that was used for data 
analysis. 
 
Pain. Subjective soreness was measured at the same time ROM was evaluated. Upon reaching 
full elbow extension, the subject indicated the degree of pain experienced on a visual pain scale 
(5). The pain scale was a 10-cm horizontal line that represented a pain continuum. The left end 
of the line represented no pain and the right end represented unbearable pain. No other 
descriptive labels were placed on the line. Each subject marked the pain scale to indicate how 
much pain was felt relative to the two descriptive terms. A new visual pain scale was used for 
each test period. Each subject's mark was then measured from the left end to the nearest 1/2 cm, 
with this measurement being used for data analysis. 
 
Exercise Protocol 
The exercise protocol that was used to induce DOMS consisted of eccentric resistive exercise to 
relative exhaustion. Each subject stood with arms to the sides while a researcher placed a 11.34-
kg dumbbell in the nondominant hand. The researcher then raised the dumbbell to the fully 
flexed elbow position. The researcher released the dumbbell and instructed the subject to lower 
the weight in a controlled manner over 3 s to full elbow extension. The researcher then raised the 
weight to the flexed-elbow position and the eccentric contraction was repeated. This process 
continued until the weight could not be controlled for 3 s, at which time the weight was reduced 
by 2.27 kg. The 9.07-kg dumbbell was used until it could not be controlled over 3 s and was then 
replaced with a 6.80-kg dumbbell, and so on. This continued until either the subject could not 
control a 2.27-kg dumbbell over the 3-s time period or the subject completed 30 repetitions with 
the 2.27-kg dumbbell. 
 
Statistical Analysis 
Concentric PT, eccentric PT, ROM, and pain were measured at the 24 hr pretest, 48 hr following 
the exercise protocol (time = 72 hr from beginning of ingestion), and 96 hr after the exercise 
protocol (time = 120 hr). Four repeated-measures ANOVAs were used to analyze the data with 




Repeated-measures ANOVA showed no significant group-by-time interaction for concentric PT, 
eccentric PT, or subjective soreness (p < .05). There was, however, a significant main effect 
across time for concentric PT (p < .001), eccentric PT (p < .001), and subjective soreness (p < 
.001). A significant groupby-time interaction was found for range of motion (p = .007). A Tukey 
post hoc test revealed a within-group effect (p < .05) from the 0 hr to 48 hr time period for both 
the treatment group and the placebo group but did not reveal a difference between groups (Table 
1). 
 
Concentric PT deficiencies at 48 and 96 hr for the placebo group were 36.1% and 23.1% of the 
pretest value, respectively, and treatment group deficiencies were 49.2% and 36.2%, respectively 
(Figure 1). Eccentric PT deficiencies at 48 and 96 hr were 40.0% and 21.8% of pretest values, 
respectively, for the placebo group and 50.0% and 37.7% of pretest values, respectively, for the 
ibuprofen group (Figure 2). Subjective soreness experienced at 48 and 96 hr for the placebo 
group was 4.4 and 1.45 (on a 0 to 10 scale), respectively, and for the treatment group was 5.70 
and 3.65, respectively (Figure 3). Decrements in elbow ROM (from active full extension) at 48 
and 96 hr for the placebo group were 22.6 and 10.6°, respectively, and for the ibuprofen group 
15.7 and 23.4°, respectively (Figure 4). 
Table 1 Analysis of Variance Statistical Summary 
 Source of variation SS DF MS F P 
Concentric Between groups      
peak torque Group .12 1 .12 4.40 .050 
 Error .50 18 .03   
 Within groups      
 Time .29 2 .14 38.82 .000 
 Group-by-time .00 2 .00 .31 .735 
 Error .13 36 .00   
Eccentric Between groups      
peak torque Group .17 1 .17 2.87 .108 
 Error 1.06 18 .06   
 Within groups      
 Time .49 2 .25 41.80 .000 
 Group-by-time .01 2 .00 .77 .470 
 Error .21 36 .01   
Subjective Between groups      
soreness Group 20.42 1 20.42 4.36 .051 
 Error 84.35 18 4.69   
 Within groups      
 Time 255.03 2 127.52 48.12 .000 
 Group-by-time 12.23 2 6.12 2.31 .114 
 Error 95.40 36 2.65   
Range of Between groups      
motion Group 176.82 1 176.82 .59 .452 
 Error 5387.83 18 299.05   
 Within groups      
 Time 4402.30 2 2201.15 25.06 .000 
 Group-by-time 999.23 2 499.62 5.69 .007* 
 Error 3162.47 36 87.85   
  
DISCUSSION 
The major finding of this study was that a comparison between ibuprofen and a placebo revealed 
no significant group-by-time interactions for concentric PT, eccentric PT, or pain. This indicates 
that there was no statistically significant difference between the ibuprofen group and the placebo 
group for any of these three testing parameters at either of the two posttests (48 and 96 hr 
postexercise). The significant main effect across time for these three parameters indicates that the 
total subject pool had different PT values at 0, 48, and 96 hr and perceived differing degrees of 
pain at 0, 48, and 96 hr. 
 
The decrease in strength and increase in perception of pain for all subjects were expected as part 
of the DOMS model used in this study. Subjects were expected to experience more pain 2 to 4 
days after exercise than they did before exercise. Based on previous studies (6, 15, 21), we 
expected peak torque to be less at 48 and 96 hr after exercise than before exercise. 
 
Concentric PT decreased in both groups, but neither the ibuprofen nor the placebo group 
decreased significantly more than the other. Evaluating the concentric PT of the entire test 
population, we found a mean deficiency of 42.7% at 48 hr and 29.7% at 96 hr. Eccentric PT 
exhibited similar results of decreased PT at 48 hr (45.0%) and 96 hr (29.8%). The deficiencies of 
concentric and eccentric PTs illustrate the main effect across time. There was a significant 
decline in PT at 48 hr and 96 hr relative to the pretest for the entire population, but one group did 
not show a greater deficiency. These results differ from the 
 
Time (hours) 
Figure 1 — Concentric peak torque per kilogram of body weight and standard deviations. *Pooled group peak torque 
at 0 hr > pooled group peak torque at 48 hr (p < .05). *Pooled group peak torque at 0 hr > pooled group peak 
torque at 96 hr (p < .05). 
 
Time (hours) 
Figure 2 — Eccentric peak torque per kilogram of body weight and standard deviations. *Pooled group peak torque at 
0 hr > pooled group peak torque at 48 hr. *Pooled group peak torque at 0 hr > pooled group peak torque at 96 hr (p 
< .05). 
 
findings of Hasson et al. (15), where concentric PT and eccentric PT deficiencies were 
significantly less in a group receiving prophylactic ibuprofen (n = 5) and a group receiving 
therapeutic ibuprofen (n = 5). Hasson et al. used both males and females, creating unequal 
distribution of each gender into each group; when the researchers evaluated quadriceps strength, 
they measured absolute isometric force production, thus ignoring the absolute strength difference 
between men and women. Although randomization resulted in an unequal distribution of males 
and females into our test groups, we measured muscular strength relative to body weight 
(Newton-meters per kilogram body weight); thus, any differences should have been minimized. 
Hasson et al. monitored test parameters only up to 48 hr postexercise and did not report 
limitations on activities of daily living. 
 
Donnelly et al. (6) tested isometric quadriceps strength in 32 subjects receiving 2,400 mg/day 
ibuprofen or a placebo. Through 72 hr after a DOMS-inducing exercise program, isometric 
quadriceps strength never decreased more than 10%. The authors found no significant difference 
between the ibuprofen or placebo group and reported that strength returned to normal levels by 
72 hr postexercise. The quadriceps muscle group was used in Donnelly et al.'s study and no 
activity limitations were reported. Like Hasson et al., Donnelly et al. evaluated muscular strength 
by measuring voluntary contraction of the quadriceps. Perhaps the greatest factor underlying the 
characteristic strength deficiency is muscular soreness. This soreness will intensify when the 
affected muscle fibers must change length during contraction, stretching, or a combination of 
both. Because of this, we believed that muscular strength evaluation through a dynamic ROM 
would show greater strength deficiencies than isometric strength testing. 
 
0 48 96 
Time (hours) 
Figure 3 — Mean visual analog pain ratings and standard deviations. *Pooled group soreness at 0 hr < group pooled 
soreness at 48 and 96 hr (p < .05). *Pooled group soreness at 48 hr > group pooled soreness at 96 hr (p < .05). 
 
Our results are similar to Donnelly et al.'s in that no difference was found, but our subject 
population still showed a significant strength deficiency 96 hr postexercise, which may be due to 
a limitation on use of the affected arm and/ or our evaluation of muscular PT through a 75° 
ROM. 
 
To our knowledge, the long-term effects of ibuprofen use in the treatment of soft tissue injury 
have not been investigated in the athletic population. By isolating a target muscle group and 
inducing an inflammatory response subsequent to injury, it is possible to investigate the effects 
of an NSAID on recovery time following injury. To maintain maximal control over the study, the 
muscle group should not undergo any other treatment and, if possible, should be immobilized. 
By using the nondominant arm and by isolating the elbow flexors, we maintained control over 
the postexercise recovery period in hope of minimizing use of the affected muscle. 
 
ROM was actually a function of subjective soreness in this study. Subjects were asked to actively 
extend the elbow to physiological limitation or to pain tolerance. Because no subject recovered 
full extension (relative to pretest values) by 96 hr, pain undoubtedly played a role in ROM 
limitation. Joint stiffness and decreased mobility are common following muscle injury, and 
movement may be discouraged more by the stiffness than by pain, but the subjects were 
extending the elbow to the point that any further extension would be too painful; thus, ROM was 
a function of how much pain subjects were experiencing. If ibuprofen did function as an 
analgesic agent in this study, it would be expected that ROM would have increased in the 
ibuprofen group. As an analgesic, ibuprofen can decrease the magnitude of pain felt but probably 
cannot elicit total relief. Thus, 
 
Time (hours) 
Figure 4 — Mean range of motion in degrees of elbow extension and standard deviations. *Mean for 
ibuprofen group at 0 hr > mean at 48 hr (p < .05). 'Mean for placebo group at 0 hr > mean at 48 hr (p < .05). 
 
there would still be a point of pain toleration, or a point at which the stimuli would elicit pain. 
Under the influence of an analgesic, this toleration point would likely be found at a greater 
magnitude of painful stimuli (i.e., increased stretch of the affected muscles). The two groups 
were expected to report similar amounts of pain because they were asked to extend the elbow to 
pain tolerance, and if ibuprofen was effective in reducing pain, the experimental group's ROM at 
absolute pain tolerance should have been greater than that of the placebo group. The ibuprofen 
probably did provide mild pain relief in the subjects, but we were assessing subjective soreness 
during a dynamic activity. We did not measure subjective soreness at a resting position, which 
may have shown a decrease in perceived pain. We viewed movement of the arm as a form of 
therapy following injury and thus tried to minimize use of the arm. Repeated movement, either 
active or passive, especially to the end range of motion likely would influence the tolerable range 
of motion while testing. Unlike the researchers investigating subjective soreness of the anterior 
thigh (quadriceps) in which walking or stair climbing would utilize active contraction and stretch 
of the muscles, we attempted to isolate a target muscle group that did not have to be used often 
during activities of daily living. 
 
There was no difference, however, between the two groups. Like the PT results, there was a 
significant deficiency in ROM at 48 hr (19.3°) and 96 hr (17.00), which illustrates the expected 
main effect across time. We expected ROM to decline up to approximately 48 hr and then 
approach pretest values. There was negligible improvement of ROM from 48 hr to 96 hr for the 
entire population (Figure 4). 
 
Further investigation into the long-term effects of ibuprofen on tissue healing and recovery is 
needed. None of the values recorded at 96 hr equaled pretest values for any of the four test 
parameters. Thus, physiological processes were still occurring as recovery continued. 
Investigation needs to be conducted well past the 96 hr time period, because the inflammatory 
response following exercise can last more than 3 weeks (9). 
 
Additionally, research needs to be directed at the effects of ibuprofen and NSAIDs on the effects 
of healing. NSAIDs are known to interfere with chemotaxis of monocytes as well as inhibit 
neutrophil aggregation (14). Monocytes produce cytokines, which are responsible for most of the 
physiological responses accompanying injury, and neutrophils produce elastase and collagenase, 
which increase vascular permeability via degradation of the vasculature and healthy tissue near 
the injury site (9). It is possible that the use of NSAIDs may impair and lengthen the healing 
process. More research should also be directed at dose-specific effects. It is likely that the 
potential impact of NSAIDs on healing time is dose dependent and that the small dose in this 
study would have a minimal impact on healing. 
 
Decreased muscular strength, decreased joint ROM, and pain have all been linked to DOMS (6-
8, 10-12, 16, 17, 21), and this study supports the evidence that each results from intense eccentric 
exercise. As found in most studies involving induced DOMS, peak values occurred at 
approximately 48 hr postexercise and, except for ROM in the ibuprofen group, approached 
pretest values thereafter. The design of this study was strengthened by the fact that relative 
immobilization of the injured muscle was achieved by using the nondominant arm, thus minimiz-
ing the effects of daily living activities. It is advised that future investigations include a control 
group. A placebo, although used to represent a "nondrug" or control group, can also elicit altered 
posttest performance values. Therefore, a control receiving no treatment should be used to 
determine if any placebo effects occur. 
 
The dosage of ibuprofen used should be carefully determined to minimize side effects and to 
attempt to standardize the dosage that is active at the site of injury. We used 2,400 mg/day 
ibuprofen because this is generally considered the highest recommended dosage to be 
administered without a physician's prescription. The FDA recommends a daily dosage of 
ibuprofen of 30-40 mg/kg body weight/day (18). This may be more applicable to a mixed gender 
study, as a subject of low body weight will probably receive much different effects from a fixed 
2,400 mg/day dosage than a subject of high body weight. 
 
In conclusion, we found that a 2,400 mg/day dose of ibuprofen taken before and following 
exercise had no significant effects compared to a placebo in the treatment of DOMS of the elbow 
flexor muscles. There is a need for further research investigating the long-term effects of 
NSAIDs on soft tissue healing. 
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